An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002.

Trial Profile

An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Bimatoprost (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions
  • Sponsors ForSight VISION5
  • Most Recent Events

    • 08 Nov 2017 According to an Allergan media release, pooled results from this and another open-label extension trial will be presented at the annual American Academy of Ophthalmology (AAO) meeting.
    • 01 Feb 2016 Status changed from active, no longer recruiting to completed.
    • 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials .gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top